Briacell Therapeutics Corp's stock has taken a hit, closing down 0.75% in the last trading session.
Briacell Therapeutics Corp (BCT.TO) saw its stock price drop to CA$3.95. This decline reflects ongoing investor concerns, especially with no significant news to support the stock's performance. With a market cap of CA$33.9 million, the company is struggling to gain traction in a competitive biotech landscape.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$48.54M
52W high
$27.20
52W low
$3.68
1W change
+6.60%
Beta
1.54
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 275.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+275.2% Upside
Current Price
C$5.33
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
64.8%
Annualized
90-Day Vol
87.4%
Annualized
Trend (90d)
-43.4%
Annualized drift
90d Mean
C$4.56
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$5.06 | C$4.05 โ C$6.33 |
| 60 trading days | C$4.81 | C$3.50 โ C$6.59 |
| 90 trading days | C$4.56 | C$3.10 โ C$6.72 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should remain cautious as Briacell's stock continues to show volatility without any recent positive developments to support a rebound.
Briacell's stock falls by 0.75% in one trading day
With a market cap of CA$33.9 million, Briacell's stock performance is particularly sensitive to market sentiment and investor confidence.
Bull case
If Briacell can leverage its innovative therapies and secure additional funding or partnerships, it might be able to turn things around.
Bear case
A continued lack of news and market interest could lead to further declines, especially given the company's small market cap and absence of a revenue stream.
Market Reaction
Briacell's stock price decline of 0.75% reflects broader market sentiment towards biotech stocks, which can be quite volatile. Investors are likely reacting to the lack of recent positive developments, creating uncertainty about the company's future.
Company Fundamentals
With a P/E ratio that isn't applicable and no profit margin reported, Briacell is in a tough spot. The company's reliance on investor confidence and funding is critical, especially considering its current market cap of CA$33.9 million.
Looking Ahead
Investors should watch for Briacell's upcoming announcements and potential partnerships. The company's ability to generate positive news could be key in reversing its stock's downward trend.
Advertisement
